Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw.
Bone turnover markers (BTMs) have become increasingly important in the management of postmenopausal osteoporosis (PMO). In bisphosphonate-treated women with PMO, BTMs can provide early indications of treatment efficacy, are predictors of BMD response and fracture risk reduction, and are potentially useful for monitoring patient compliance. The bone resorption marker serum C-telopeptide cross-link of type 1 collagen (sCTX) has shown high sensitivity and specificity for the detection of increased bone resorption. Recently, sCTX has been singled out as a potential indicator of risk of osteonecrosis of the jaw (ONJ) in patients receiving oral bisphosphonates who require oral surgery. However, whether BTMs are capable of predicting ONJ risk and whether sCTX is usable for this purpose are controversial questions. This article presents an overview of the current literature regarding critical issues affecting the clinical utility of BTMs (including variability and reference ranges) and the current applications of BTMs in PMO management, with a focus on sCTX. Last, the appropriateness of using sCTX to predict ONJ risk in women receiving oral bisphosphonates for PMO is evaluated.
Baim
Sanford
S
Colorado Center for Bone Research, Lakewood, Colorado 80227, USA.
Miller
Paul D
PD
D015415:Biomarkers / Q000378:metabolism; D024042:Collagen Type I / Q000097:blood*; D005260:Female; D006801:Humans; D007571:Jaw Diseases / Q000097:blood / Q000150:complications*; D010020:Osteonecrosis / Q000097:blood / Q000150:complications*; D015663:Osteoporosis, Postmenopausal / Q000097:blood* / Q000150:complications*; D010455:Peptides / Q000097:blood*; D012307:Risk Factors
D015415:Biomarkers; D024042:Collagen Type I; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide